This is a single-center, prospective, single-arm, phase II clinical study, to evaluate the therapeutic efficacy and safety of envafolimab combined with chemoradiotherapy and recombinant human endostatin in patients with locally advanced nasopharyngeal carcinoma.
ECOG score 0-1.
Aged 18-65 years, male or non-pregnant female;
Pathologically confirmed diagnosis of nasopharyngeal non-keratinizing carcinoma (differentiated or undifferentiated, WHO type II or III) without the need to detect MSI and dMMR status.
high-risk locally advanced stage III-IVA (8th AJCC/UICC staging), i.e., T4N+ or N2-3, or pretreatment EBV-DNA ≥4000 copies/ml, or lymph node extra-envelope invasion grade 3 (invasion of muscle skin, etc.), treatment-naive nasopharyngeal carcinoma patients.
Patients with recurrent nasopharyngeal carcinoma and distant metastasis.
Pathology was keratinizing squamous cell carcinoma (WHO classification type I).
Patients who have undergone radiotherapy or systemic chemotherapy;
Pregnant or lactating women, in the reproductive period without effective contraceptive measures;